Cyramza® (ramucirumab) – New indication and boxed warning removal
May 13, 2019 - Eli Lilly announced the FDA approval of Cyramza (ramucirumab), as a single agent, for the treatment of hepatocellular carcinoma (HCC) in patients who have an alpha fetoprotein (AFP) of ≥ 400 ng/mL and have been treated with Nexavar® (sorafenib).
Top